PersPeCtive
Introduction
B cell precursors within the bone marrow represent the normal counterpart of ~85 percent of acute lymphoblastic leukemia (ALL) cases. Pre-B cells are destined to die by apoptosis within the bone marrow unless they are rescued through survival signals from a successfully assembled pre-B cell receptor. 1 During normal early B cell development, the pre-B cell receptor has a dual function-it first promotes survival and proliferation of large cycling pre-B cells and subsequently induces differentiation in small resting pre-B cells. [2] [3] [4] It consists of an immunoglobulin μ heavy chain (μ chain; IGHM) coupled to the surrogate light chain with its two components VpreB (VPREB1) and λ5 (IGLL1). 5, 6 Productive rearrangement of immunoglobulin V H to DJ H gene segments is a prerequisite for the expression of a functional μ chain and hence the transition from the pro-B to pre-B cell stage. 1 This extracellular part of the pre-B cell receptor is linked to the Igα and Igβ transmembrane signaling chains, which contain an immunoreceptor tyrosine-based activation motif (ITAM) in their intracellular tail. 7 The cytoplasmic ITAM-bearing signaling chains mainly serve as a docking sites to assemble and activate the igniting components of the pre-B cell receptor signaling cascade, namely SYK (spleen tyrosine kinase), the SRC family kinases LYN, FYN and BLK, and Bruton's tyrosine kinase (BTK). 8 BTK binds to and activates PLCγ2 (PLCG2), a key enzyme for hydrolysis of PI(4,5)P 2 . Thereby, PLCγ2 generates diacylglycerol and IP3, which serve as second messengers for activation of PKCs and Ca 2+ release from cytoplasmic stores, respectively. SLP65 (or BLNK, BASH), 9 is a major linker protein to assemble the proximal signaling components of pre-B cell receptor. It has specific docking sites for BTK and PLCγ2 (Fig. 1) . 10 In the absence of SLP65, the function of the pre-B cell receptor is PersPeCtive PersPeCtive receptor signaling effectively suppresses leukemic growth in Ph + ALL. How the pre-B cell receptor and its downstream signaling molecules (e.g., SLP65) mediate this tumor suppression is still a subject of ongoing studies. One mechanism could be inhibition of active kinases like JAK3. 22 We found Ikaros to be one essential factor downstream of the pre-B cell receptor required for this tumor suppression. Ikaros family transcription factorsespecially Ikaros and Aiolos are required for B cell development to progress. 23 B and T cell development is arrested in Ikaros-deficient mice, and they also have abnormal myelopoiesis. 24 Deficiency of Aiolos too, is shown to cause aberrant B cell development. 25 Of note, deletions of the Ikzf1 gene encoding Ikaros represent a near-obligatory lesion in Ph + ALL, which is found in more than 80% of the cases. 26 Interestingly, small deletions within the Ikzf1 gene lead to expression of a dominant-negative Ikaros protein (IK6), which can also be expressed as a result of aberrant pre-mRNA splicing. 27 Expression of dominant negative Ikaros splice variant IK6 blocked the tumorsuppressive effect of the pre-B cell receptor. 21 Further mechanistic studies are still ongoing to delineate how the pre-B cell receptor and its downstream targets SLP65 and Ikaros cooperate in this tumor-suppressive effect.
Distinct Functions of the Pre-B Cell Receptor in Cytogenetic ALL
Subtypes?
While a differentiation block at the pro-B or pre-B cell stage represents a uniform feature for ALL, there are heterogeneous cytogenetic subtypes of the disease. In human ALL, four major oncogenic gene rearrangements are recurrently found, namely E2A-PBX1, BCR-ABL1 (resulting from the Philadelphia chromosome), MLL-AF4 and TEL-AML1. Additional cytogenetic subgroups of ALL include cases with sporadic gene rearrangements and cases with hyper-and hypodiploid or normal karyotype. 28 Whereas E2A-PBX1, MLL-AF4 and TEL-AML1 encode oncogenic transcription factors, the BCR-ABL1 fusion gene codes for a constitutively active tyrosine kinase.
Development of Acute Lymphoblastic Leukemia from Pre-B Cell Receptor-Independent
Stages of B Cell Development B cell lineage acute lymphoblastic leukemia (ALL) is virtually in all cases derived from pro-B or pre-B cells that are arrested in their development. Lack of SLP65 (BLNK) function in a substantial fraction of cases of ALL [15] [16] [17] [18] represents one explanation for this differentiation block. Also expression of BTK, which in addition to SLP65 is required for pre-B cell receptor function, is aberrant or missing in many cases of ALL. 19 Recent data on the absence of functional pre-B cell receptor signaling in Philadelphia chromosome-positive (Ph + ) ALL 21 highlights the role of the pre-B cell receptor as tumor suppressor. Reconstitution of pre-B cell compromised and SLP65-deficient B cell precursors are arrested at the pre-B cell stage. 11 Once rearrangement of immunoglobulin V H to DJ H gene segments is successfully completed, the pre-B cell receptor is assembled, expressed on the cell surface and delivers a strong proliferation signal to the developing pre-B cells, which then drastically expand within the bone marrow. Subsequently, the pre-B cell receptor initiates immunoglobulin κ light chain gene rearrangements via signals through SLP65 indicating the importance of SLP65 in pre-B cell differentiation. 12, 13 After successful rearrangement at the light chain locus, the B cell receptor carrying the definitive κ chain instead of surrogate light chains replaces the pre-B cell receptor.
14 At this time, IgMκ + immature B cells leave the bone marrow. Figure 1 . the pre-B cell receptor complex consisting of the μ-heavy chain (Ighm), the surrogate light chain components vpreB and λ5 (Igll1) and the igα signaling chain (Cd79a) are shown. Proximal pre-B cell receptor signaling involves the tyrosine kinases sYK, BtK and PLCγ2 (PLCG2), which are assembled through specific docking sites to the linker molecule SLP65. BtK and PLCγ2 are anchored to the membrane by binding to PiP3. PLCγ2 hydrolyzes PiP2 to iP3 and DAG. the latter activates PKC, whereas the former induces release of Ca 2+ from stores within the endoplasmic reticulum.
aberrant expression of the mutator enzyme AID in this subtype of ALL. 39 The high frequency of defects in the pre-B cell receptor-related signaling molecules in ALL cells identified by others [16] [17] [18] [19] and us suggests that the pre-B cell receptor may counteract malignant transformation especially in Ph + ALL. On the other hand, the pre-B cell receptor also delivers critical survival and proliferation signals in early B cell precursors and its expression is required for abnormal lymphoproliferation. 15 In addition, previous work demonstrated that the pre-B cell receptor and the pre-B cell receptor-related tyrosine kinase Syk are required for Myc-mediated transformation of pre-B cells. 40 Our group recently demonstrated that the pre-B cell receptor-related signaling molecule BTK plays a central role in the oncogenic signaling complex activated by BCR-ABL1. 20 Based on these findings, it is currently unclear whether pre-B cell receptor signaling is required to enable malignant outgrowth in ALL or functions to suppress it.
Hypothesis. Congenital defects in pre-B cell receptor-related signaling molecules cause a severe block of early B cell development in humans. 41 For instance, inherited mutations of the IGLL1 (λ5),
42
CD79A (Igα), 43 CD79B (Igβ), 44 SLP65 (BLNK) 45 and IGHM genes (μ-chain) 46 all lead to compromised pre-B cell receptor function and all lead to a severe B cell differentiation block at or before the pre-B cell stage. Likewise, in acute lymphoblastic leukemia (ALL), a malignancy derived from B cell precursors in most cases, cells are arrested at early stages of B cell development. In previous studies from our group, we found defective expression of IGLL1, CD79B, IGHM and SLP65, 17 29 Interestingly, the chimeric E2A-PBX1 transcription factor induces aberrant expression of WNT16, 30 which could lead to autocrine stimulation of the LEF1/WNT/β-catenin pathway in these cells.
The t(4;11)(q21;q23) translocation leading to the expression of the chimeric MLL-AF4 transcription factors is associated with a particularly unfavorable prognosis and found in ~50% of cases with infant leukemia. 31 Owing to aberrant MLL-AF4 transcription factor activity, MLL-AF4-expressing leukemia cells typically exhibit a mixed B cell/myeloid cell lineage phenotype, which led to the designation of the MLL gene typically rearranged in this type of leukemia as "mixed lineage leukemia" gene. 32 In addition, the oncogenic MLL-AF4 transcription factor also induces upregulation of the stem cell antigen Prominin1 (CD133), 33 which is aberrantly expressed on cancer stem cells in a variety of malignancies.
The t(9;22)(q34;q11) chromosomal rearrangement leading to the so-called Philadelphia chromosome (Ph) 34 and expression of the oncogenic BCR-ABL1 tyrosine kinase, 35 represents the most frequent cytogenetic abnormality in adult ALL (about 25-30% of cases) 36 and also occurs in childhood ALL (4-5%). 37 Unlike the normal ABL1 kinase, BCR-ABL1 is constitutively active and previous work by our group showed that BCR-ABL1 mimics survival signals from a constitutively active pre-B cell receptor, mainly through tyrosine phosphorylation of BTK. 17, 20 Unlike other oncogenic gene rearrangements in ALL, the BCR-ABL1 fusion gene is required and sufficient for malignant transformation of B cell precursors. 38 Among all cytogenetic subtypes of ALL, the BCR-ABL1 fusion gene defines the subgroup of ALL with the worst clinical prognosis. 31 The main reason for the unfavorable clinical outcome of BCR-ABL1 ALL is genetic instability, likely owing to
